OrbiMed Advisors
Latest statistics and disclosures from Orbimed Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SVA, BMY, HUM, HZNP, BSX, and represent 18.96% of Orbimed Advisors's stock portfolio.
- Added to shares of these 10 stocks: SVA (+$350M), XENE (+$20M), MRSN (+$20M), TVTX (+$19M), PGNY (+$18M), IONS (+$17M), Global Blood Therapeutics In (+$13M), REGN (+$13M), ISEE (+$13M), ALXO (+$13M).
- Started 12 new stock positions in KZR, KALV, PGNY, IONS, SRRK, NVAX, EYPT, TVTX, REGN, ISEE. SVA, APLT.
- Reduced shares in these 10 stocks: DXCM (-$77M), PFE (-$61M), IOVA (-$42M), NSTG (-$40M), MRTX (-$36M), ARQT (-$28M), ABBV (-$18M), TBPH (-$17M), RARE (-$17M), ILMN (-$16M).
- Sold out of its positions in ALBO, ASLN, CABA, DXCM, EXAI, Field Trip Health Ord, GLPG, IMAB, ILMN, LABP. NSTG, OWLT.WS, PYXS, RARE.
- Orbimed Advisors was a net buyer of stock by $133M.
- Orbimed Advisors has $5.5B in assets under management (AUM), dropping by -10.52%.
- Central Index Key (CIK): 0001055951
Tip: Access up to 7 years of quarterly data
Positions held by OrbiMed Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Orbimed Advisors
Orbimed Advisors holds 139 positions in its portfolio as reported in the June 2022 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Sinovac Biotech SHS (SVA) | 6.3 | $350M | NEW | 2.7M | 128.55 | |
| Bristol Myers Squibb (BMY) | 3.5 | $194M | -3% | 2.5M | 77.00 | |
| Humana (HUM) | 3.1 | $171M | -4% | 366k | 468.07 | |
| Horizon Therapeutics Pub L SHS (HZNP) | 3.0 | $168M | -4% | 2.1M | 79.76 | |
| Boston Scientific Corporation (BSX) | 3.0 | $163M | -5% | 4.4M | 37.27 | |
| Turning Point Therapeutics I | 2.7 | $151M | 2.0M | 75.25 | ||
| Springworks Therapeutics (SWTX) | 2.7 | $148M | 6.0M | 24.62 | ||
| UnitedHealth (UNH) | 2.6 | $144M | -4% | 281k | 513.63 | |
| Pfizer (PFE) | 2.6 | $144M | -29% | 2.7M | 52.43 | |
| BioMarin Pharmaceutical (BMRN) | 2.6 | $141M | +3% | 1.7M | 82.87 | |
| Seagen (SGEN) | 2.4 | $131M | +10% | 738k | 176.94 | |
| Abbvie (ABBV) | 2.2 | $123M | -12% | 800k | 153.16 | |
| Edgewise Therapeutics (EWTX) | 2.0 | $112M | 14M | 7.96 | ||
| Vertex Pharmaceuticals Incorporated (VRTX) | 2.0 | $109M | -3% | 387k | 281.79 | |
| Adicet Bio (ACET) | 2.0 | $109M | 7.4M | 14.60 | ||
| Sierra Oncology Com New | 2.0 | $108M | 2.0M | 54.99 | ||
| Biohaven Pharmaceutical Holding | 1.9 | $105M | 719k | 145.71 | ||
| Intuitive Surgical Com New (ISRG) | 1.9 | $104M | -3% | 517k | 200.71 | |
| Arcutis Biotherapeutics (ARQT) | 1.8 | $102M | -21% | 4.8M | 21.31 | |
| Tricida (TCDA) | 1.8 | $100M | 10M | 9.68 | ||
| Edwards Lifesciences (EW) | 1.7 | $96M | -3% | 1.0M | 95.09 | |
| Theseus Pharmaceuticals (THRX) | 1.7 | $94M | 17M | 5.53 | ||
| Pmv Pharmaceuticals (PMVP) | 1.7 | $94M | -4% | 6.6M | 14.25 | |
| Stryker Corporation (SYK) | 1.6 | $88M | -3% | 441k | 198.93 | |
| Neurocrine Biosciences (NBIX) | 1.5 | $83M | -2% | 850k | 97.48 | |
| Argenx Se Sponsored Adr (ARGX) | 1.3 | $74M | +14% | 194k | 378.88 | |
| Mirati Therapeutics (MRTX) | 1.3 | $73M | -33% | 1.1M | 67.13 | |
| Global Blood Therapeutics In | 1.2 | $65M | +25% | 2.0M | 31.95 | |
| Natera Call Option (NTRA) | 1.2 | $64M | +3% | 1.8M | 35.44 | |
| Thermo Fisher Scientific (TMO) | 1.1 | $62M | -5% | 113k | 543.28 | |
| Crinetics Pharmaceuticals In (CRNX) | 1.1 | $60M | 3.2M | 18.65 | ||
| Compass Therapeutics (CMPX) | 1.1 | $58M | 22M | 2.65 | ||
| Evolent Health Cl A (EVH) | 1.0 | $55M | +27% | 1.8M | 30.71 | |
| Ikena Oncology Nonvoting | 1.0 | $54M | +2% | 12M | 4.43 | |
| Prelude Therapeutics (PRLD) | 1.0 | $52M | 10M | 5.22 | ||
| Kinnate Biopharma (KNTE) | 0.9 | $51M | 4.0M | 12.61 | ||
| Abcellera Biologics (ABCL) | 0.9 | $47M | +5% | 4.4M | 10.65 | |
| Repare Therapeutics Ord (RPTX) | 0.8 | $47M | 3.3M | 13.99 | ||
| Keros Therapeutics (KROS) | 0.8 | $46M | 1.7M | 27.63 | ||
| Syndax Pharmaceuticals (SNDX) | 0.8 | $45M | +7% | 2.3M | 19.24 | |
| Si-bone (SIBN) | 0.8 | $45M | +7% | 3.4M | 13.20 | |
| Guardant Health Call Option (GH) | 0.8 | $44M | -18% | 1.1M | 40.34 | |
| Gracell Biotechnologies Sponsored Ads (GRCL) | 0.8 | $43M | 7.9M | 5.50 | ||
| Mersana Therapeutics (MRSN) | 0.8 | $42M | +88% | 9.0M | 4.62 | |
| Xenon Pharmaceuticals (XENE) | 0.7 | $40M | +93% | 1.3M | 30.42 | |
| Xtant Med Hldgs Com New (XTNT) | 0.7 | $38M | 73M | 0.52 | ||
| Silverback Therapeutics (SPRY) | 0.7 | $37M | 8.7M | 4.24 | ||
| Vectivbio Hldg Ord Shs (VECT) | 0.6 | $35M | +21% | 6.5M | 5.40 | |
| Alpine Immune Sciences (ALPN) | 0.6 | $35M | 4.1M | 8.51 | ||
| Janux Therapeutics (JANX) | 0.6 | $35M | 2.8M | 12.21 | ||
| Tenet Healthcare Corp Com New (THC) | 0.6 | $35M | +4% | 656k | 52.56 | |
| Chinook Therapeutics (KDNY) | 0.6 | $33M | +33% | 1.9M | 17.49 | |
| Vaxcyte (PCVX) | 0.6 | $33M | 1.5M | 21.76 | ||
| Aclaris Therapeutics (ACRS) | 0.6 | $33M | +47% | 2.3M | 13.96 | |
| Iovance Biotherapeutics (IOVA) | 0.6 | $31M | -57% | 2.8M | 11.04 | |
| Verona Pharma Sponsored Ads (VRNA) | 0.4 | $24M | 5.7M | 4.19 | ||
| Scpharmaceuticals (SCPH) | 0.4 | $23M | 4.8M | 4.82 | ||
| Biogen Idec (BIIB) | 0.4 | $23M | -5% | 112k | 203.94 | |
| Tela Bio (TELA) | 0.4 | $21M | 3.0M | 7.01 | ||
| Passage Bio (PASG) | 0.4 | $21M | +21% | 8.9M | 2.36 | |
| Decibel Therapeutics (DBTX) | 0.4 | $21M | 4.9M | 4.21 | ||
| Neuropace (NPCE) | 0.4 | $20M | 4.0M | 4.95 | ||
| Rxsight (RXST) | 0.4 | $20M | 1.4M | 14.08 | ||
| Meiragtx Holdings (MGTX) | 0.3 | $19M | -24% | 2.5M | 7.57 | |
| Travere Therapeutics (TVTX) | 0.3 | $19M | NEW | 772k | 24.23 | |
| Progyny (PGNY) | 0.3 | $18M | NEW | 625k | 29.05 | |
| Gilead Sciences (GILD) | 0.3 | $18M | 288k | 61.81 | ||
| Alx Oncology Hldgs (ALXO) | 0.3 | $18M | +251% | 2.2M | 8.09 | |
| Ionis Pharmaceuticals (IONS) | 0.3 | $17M | NEW | 453k | 37.02 | |
| Adagio Therapeutics (IVVD) | 0.3 | $17M | 5.1M | 3.28 | ||
| Uniqure Nv SHS (QURE) | 0.3 | $16M | -4% | 875k | 18.64 | |
| Gh Research Ordinary Shares (GHRS) | 0.3 | $16M | +13% | 1.6M | 9.98 | |
| Rapt Therapeutics (RAPT) | 0.3 | $16M | +139% | 866k | 18.25 | |
| Ventyx Biosciences (VTYX) | 0.3 | $16M | 1.3M | 12.23 | ||
| Amgen (AMGN) | 0.3 | $14M | 57k | 243.29 | ||
| Bellus Health Com New (BLU) | 0.2 | $13M | 1.5M | 9.20 | ||
| Regeneron Pharmaceuticals (REGN) | 0.2 | $13M | NEW | 22k | 591.13 | |
| Iveric Bio (ISEE) | 0.2 | $13M | NEW | 1.4M | 9.62 | |
| Ikena Oncology (IKNA) | 0.2 | $13M | 2.9M | 4.43 | ||
| Nextcure (NXTC) | 0.2 | $13M | 2.7M | 4.70 | ||
| Signify Health Cl A Com (SGFY) | 0.2 | $12M | +44% | 900k | 13.80 | |
| Theravance Biopharma (TBPH) | 0.2 | $12M | -57% | 1.4M | 9.06 | |
| Bridgebio Pharma Note 2.250% 2/0 (Principal) | 0.2 | $12M | 30M | 0.41 | ||
| Vistagen Therapeutics Com New (VTGN) | 0.2 | $12M | +3% | 13M | 0.88 | |
| 89bio (ETNB) | 0.2 | $12M | 3.7M | 3.22 | ||
| Kezar Life Sciences (KZR) | 0.2 | $12M | NEW | 1.4M | 8.27 | |
| Milestone Pharmaceuticals (MIST) | 0.2 | $11M | -29% | 1.8M | 6.15 | |
| Mereo Biopharma Group Ads (Principal) (MREO) | 0.2 | $11M | -43% | 9.7M | 1.12 | |
| Danaher Corporation 5% Conv Pfd B (Principal) (DHR.PB) | 0.2 | $11M | 8.0k | 1323.17 | ||
| Gemini Therapeutics | 0.2 | $9.8M | 5.8M | 1.69 | ||
| Chemomab Therapeutics Sponsored Ads (CMMB) | 0.2 | $9.5M | 2.6M | 3.70 | ||
| Terns Pharmaceuticals (TERN) | 0.2 | $9.4M | 3.8M | 2.48 | ||
| Oric Pharmaceuticals (ORIC) | 0.2 | $9.4M | 2.1M | 4.48 | ||
| Erasca (ERAS) | 0.2 | $9.3M | 1.7M | 5.57 | ||
| Bridgebio Pharma Note 2.500% 3/1 (Principal) | 0.2 | $9.0M | 20M | 0.45 | ||
| Jounce Therapeutics (JNCE) | 0.2 | $8.9M | +2% | 2.9M | 3.03 | |
| Cullinan Oncology (CGEM) | 0.2 | $8.6M | 671k | 12.82 | ||
| Spdr Ser Tr S&p Biotech (XBI) | 0.2 | $8.3M | 112k | 74.27 | ||
| Fusion Pharmaceuticals (FUSN) | 0.1 | $8.0M | 3.2M | 2.49 | ||
| Aerovate Therapeutics (AVTE) | 0.1 | $7.5M | -6% | 479k | 15.63 | |
| Galecto (GLTO) | 0.1 | $7.1M | 4.1M | 1.73 | ||
| Synlogic (SYBX) | 0.1 | $6.9M | 6.0M | 1.15 | ||
| Corvus Pharmaceuticals (CRVS) | 0.1 | $6.9M | 6.9M | 0.99 | ||
| Pulmonx Corp (LUNG) | 0.1 | $6.4M | 435k | 14.72 | ||
| Scholar Rock Hldg Corp (SRRK) | 0.1 | $5.9M | NEW | 1.1M | 5.49 | |
| Cybin Ord (CYBN) | 0.1 | $5.9M | 11M | 0.56 | ||
| Harpoon Therapeutics (HARP) | 0.1 | $5.8M | 3.0M | 1.91 | ||
| Mirum Pharmaceuticals (MIRM) | 0.1 | $5.4M | +935% | 280k | 19.46 | |
| Imara (IMRA) | 0.1 | $5.4M | 4.4M | 1.22 | ||
| Immunocore Hldgs Ads (IMCR) | 0.1 | $4.9M | +2% | 131k | 37.31 | |
| Nanostring Technologies Note 2.625% 3/0 (Principal) | 0.1 | $4.9M | 6.0M | 0.81 | ||
| Graybug Vision Com Shs (GRAY) | 0.1 | $4.5M | 4.2M | 1.09 | ||
| Vor Biopharma (VOR) | 0.1 | $4.1M | 833k | 4.97 | ||
| Burning Rock Biotech Sponsored Ads (BNR) | 0.1 | $4.0M | -4% | 1.4M | 2.91 | |
| Applied Therapeutics (APLT) | 0.1 | $4.0M | NEW | 4.3M | 0.95 | |
| Achilles Therapeutics Sponsored Ads (ACHL) | 0.1 | $4.0M | 1.6M | 2.52 | ||
| Cytomx Therapeutics (CTMX) | 0.1 | $3.9M | 2.1M | 1.83 | ||
| Novavax Com New Call Option (NVAX) | 0.1 | $3.9M | NEW | 75k | 51.43 | |
| Celldex Therapeutics Com New (CLDX) | 0.1 | $3.0M | -72% | 113k | 26.96 | |
| Logicbio Therapeutics | 0.1 | $3.0M | 8.5M | 0.35 | ||
| Acutus Medical (AFIB) | 0.1 | $3.0M | 2.6M | 1.12 | ||
| Magenta Therapeutics (MGTA) | 0.0 | $2.7M | 2.3M | 1.20 | ||
| Oncocyte (OCX) | 0.0 | $2.6M | -18% | 2.8M | 0.90 | |
| Protara Therapeutics Com Stk (TARA) | 0.0 | $2.4M | 831k | 2.93 | ||
| Graphite Bio (GRPH) | 0.0 | $2.3M | -45% | 848k | 2.75 | |
| 9 Meters Biopharma | 0.0 | $2.2M | -17% | 8.5M | 0.26 | |
| Singular Genomics Systems In (OMIC) | 0.0 | $2.1M | -76% | 541k | 3.82 | |
| Chardan Healthcare Acqu- Ord (PHGE) | 0.0 | $2.1M | 2.8M | 0.73 | ||
| Kalvista Pharmaceuticals (KALV) | 0.0 | $1.8M | NEW | 185k | 9.84 | |
| Sight Sciences (SGHT) | 0.0 | $1.8M | 200k | 8.99 | ||
| Eyepoint Pharmaceuticals Com New (EYPT) | 0.0 | $1.7M | NEW | 214k | 7.87 | |
| Sarepta Therapeutics (SRPT) | 0.0 | $1.5M | -48% | 20k | 74.95 | |
| X4 Pharmaceuticals (XFOR) | 0.0 | $1.3M | 1.4M | 0.97 | ||
| Sonendo (SONX) | 0.0 | $1.2M | -63% | 724k | 1.72 | |
| Talaris Therapeutics (TALS) | 0.0 | $1.1M | -4% | 236k | 4.51 | |
| Vigil Neuroscience (VIGL) | 0.0 | $1.1M | 411k | 2.58 | ||
| Aeglea Biotherapeutics (AGLE) | 0.0 | $908k | -39% | 1.8M | 0.51 | |
| Longboard Pharmaceuticals In (LBPH) | 0.0 | $351k | 114k | 3.09 | ||
| Aptinyx (APTX) | 0.0 | $300k | 539k | 0.56 |
Past Filings by Orbimed Advisors
SEC 13F filings are viewable for Orbimed Advisors going back to 2010
- Orbimed Advisors 2022 Q2 filed Aug. 15, 2022
- Orbimed Advisors 2022 Q1 filed May 16, 2022
- Orbimed Advisors 2021 Q4 filed Feb. 14, 2022
- Orbimed Advisors 2021 Q3 filed Nov. 15, 2021
- Orbimed Advisors 2021 Q2 filed Aug. 16, 2021
- Orbimed Advisors 2021 Q1 filed May 17, 2021
- Orbimed Advisors 2020 Q4 filed Feb. 16, 2021
- Orbimed Advisors 2020 Q3 filed Nov. 16, 2020
- Orbimed Advisors 2020 Q2 filed Aug. 14, 2020
- Orbimed Advisors 2020 Q1 filed May 15, 2020
- Orbimed Advisors 2019 Q4 filed Feb. 14, 2020
- Orbimed Advisors 2019 Q3 filed Nov. 14, 2019
- Orbimed Advisors 2019 Q2 filed Aug. 14, 2019
- Orbimed Advisors 2019 Q1 filed May 15, 2019
- Orbimed Advisors 2018 Q4 filed Feb. 14, 2019
- Orbimed Advisors 2018 Q3 filed Nov. 14, 2018